Physician profile
Michael J Benoit
NPI 1235199795
$602.50
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.63 · 2020: $12.72 · 2021: $86.03 · 2022: $205 · 2023: $144 · 2024: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $121.04 | 2022 | |
| Intuitive Surgical, INC. | $90.91 | 2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $62.77 | 2019-2024 | Shingrix, Arexvy |
| Abbott Laboratories | $48.63 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $46.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.72 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $41.95 | 2024 | Qelbree |
| Amgen INC. | $30.40 | 2021-2022 | |
| Ardelyx, INC. | $27.11 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $19.40 | 2022 | |
| Baxter Healthcare | $17.40 | 2019 | |
| Biomerieux INC | $13.04 | 2021 | |
| Biofire Diagnostics, LLC | $13.04 | 2021 | |
| Novo Nordisk INC | $12.72 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Benoit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.